Use of systemic chemotherapy against central nervous system (CNS) tumors is limited by the inability of the drugs to cross the blood-brain barrier. Despite this limitation, the combination of cisplatin plus etoposide has demonstrated moderate overall response in breast cancer patients with brain metastases who have not received whole brain radiation. 1, 2 The addition of bevacizumab, a humanized recombinant monoclonal antibody active against vascular endothelial growth factor, has been shown to induce vascular normalization of brain metastases and potentiate the combined cisplatin and etoposide antitumor effect. 3-5
2. Dilute in 250 to 1000 mL of NS or a saline/dextrose solution. 3. To ensure stability, cisplatin infusion concentration must have a final chloride ion concentration of at least 0.2%. 4. Stability varies based on chloride ion concentration.
Drug Administration
A. Bevacizumab 1. Should not be administered within 28 days of major surgery, or until the surgical wound is fully healed. 2. Infuse the first dose over 90 minutes. 3 . If the first dose is tolerated well, infuse the second dose over 60 minutes. 4. If the second dose is tolerated well, all subsequent doses may be infused over 30 minutes.
B. Etoposide 1. Administer by intravenous (IV) infusion over 45 to 60 minutes. 2. Use a 0.22-µm inline filter to reduce precipitate risk. 3. Infusions with a duration less than 30 minutes greatly increase the incidence of hypotension.
C. Cisplatin is usually administered as a 30-minute to 1 hour IV infusion.
Supportive Care

A. Acute and Delayed Emesis Prophylaxis
The BEEP regimen is predicted to cause acute emesis in greater than 90% of patients. 11 However, the expected emetogenicity of the BEEP regimen varies according to the day of the regimen. The studies reviewed reported mild to moderate (grade 1 or 2) nausea or vomiting in 15% to 27% of completed cycles 3, 4 ; severe (grade 3 or 4) nausea or vomiting was reported in 1%. 3 On day 2, when cisplatin and etoposide are administered, or days 3 and 4, when etoposide alone is administered, the risk of nausea or vomiting is higher than on day 1 when only bevacizumab is administered. 11 One of the following regimens is suggested:
Day 1:
For most patients, prophylactic antiemetic therapy, particularly with a serotonin antagonist, is not required. [12] [13] [14] However, patients who do experience nausea or vomiting on day 1 will require a prophylactic antiemetic regimen for subsequent cycles of therapy.
Patients who experience significant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category added to the previous prophylactic antiemetic regimen. [11] [12] [13] [14] One of the following regimens is recommended:
1. Patients who received a steroid only-Add a dopamine antagonist.
Patients who received a dopamine antagonist only-
Add a steroid. 3. Patients who received a steroid and dopamine antagonist-Substitute a serotonin antagonist for the dopamine antagonist.
Day 2:
Appropriate acute emesis prophylaxis includes a serotonin antagonist, a corticosteroid, and a neurokinin (NK 1 ) antagonist. [12] [13] [14] One of the following regimens is recommended:
1. Ondansetron 16 mg to 24 mg, dexamethasone 12 mg, 30 minutes before BEEP on day 2. 2. Granisetron 2 mg, dexamethasone 12 mg, before BEEP on day 2. Cisplatin 60 mg/m 2 IV on day 1, etoposide 120 mg/m 2 IV on days 1 through 3, and bevacizumab 15 mg/kg IV on day 1, every 3 weeks for up to 4 cycles. 6 2. Cisplatin 30 mg/m 2 IV on days 1 through 3, etoposide 50 mg/m 2 PO on days 1 through 15, and bevacizumab 5 mg/kg IV on day 3, every 3 weeks. 7 3. Cisplatin 25 mg/m 2 , etoposide 100 mg/m 2 IV on days 1 through 3, bevacizumab 7.5 mg/kg IV day 1, every 3 weeks for 6 cycles. 8 3. Dolasetron 100 mg, dexamethasone 12 mg, PO 30 minutes before BEEP on day 2. 4. Palonosetron 0.25 mg IV, dexamethasone 12 mg, PO 30 minutes before BEEP on day 2. Palonosetron should not be used if given earlier in the cycle.
One of the following neurokinin antagonist options should be used with one of the above regimens: The antiemetic therapy should continue for at least 3 days. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (greater than 24 hours) use of these agents, making a steroid, or steroid and dopamine antagonist combination most appropriate for follow-up therapy. 15 One of the following regimens is recommended: Patients who do experience significant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. [11] [12] [13] [14] There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles, or increasing the dose, even to very high doses, is effective. This approach is generally not recommended. [16] [17] [18] [19] [20] Cisplatin in doses of >50 mg/m 2 (either as a single dose or cumulative over consecutive days) is reported to cause delayed nausea in 78% of patients and delayed emesis in 61% of patients. Delayed nausea or emesis may begin as soon as 16 hours after cisplatin administration, reach their peak of severity at 48 to 72 hours after cisplatin administration, and usually abate between 96 and 168 hours after cisplatin administration. 21
B. Breakthrough Nausea and Vomiting 11-14
Patients should receive a prescription for an antiemetic to treat breakthrough nausea. One of the following regimens is recommended: Patients who do experience significant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. [11] [12] [13] [14] There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles, or increasing the dose, even to very high doses, is effective. This approach is not recommended. [16] [17] [18] [19] [20] 
C. Hydration
Cisplatin can cause irreversible kidney damage by acute tubular necrosis. Maintenance of a urine output of greater than or equal to 75 to 100 mL/h for several hours before and after each cisplatin dose is the best prophylaxis against cisplatin-induced nephrotoxicity. A wide variety of hydration and diuretic regimens for this purpose have been reported. Cornelison and Reed reported that, with the possible exception of the first treatment cycle, diuretics add nothing to vigorous hydration for prevention of cisplatin nephrotoxicity. 22 Kintzel noted the mechanism of action of diuretics intuitively supports their use to prevent cisplatin-induced nephrotoxicity, but there is no evidence to recommend their use over vigorous hydration. 23 A suggested hydration regimen is 5% dextrose/0.9% sodium chloride injection or 0.9% sodium chloride injection, infused at 250 mL/h for 2 to 4 hours before and after each cisplatin dose. Oral hydration regimens are also used, but the increased chloride from IV sodium chloride injections may offer better renal protection. 22
D. Hematopoietic Growth Factors
Accepted practice guidelines and pharmacoeconomic analysis suggest that antineoplastic regimens have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony-stimulating factors is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of colony-stimulating factors should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of colony-stimulating factors is not recommended. 24, 25 Lu et al reported febrile neutropenia in 2% of treatment cycles. 3 In studies reviewed, severe (grade 3 or 4) neutropenia was found in up to 57% of cycles. 3, 4 As febrile neutropenia was reported in only 2% of patients in the trials of BEEP, prophylactic use of colony-stimulating factors is not recommended. 25, 26 Colony-stimulating factors should be considered if a patient experiences febrile neutropenia or grade 4 neutropenia in a prior cycle of BEEP.
Major Toxicities
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute Common Terminology Criteria for Adverse Events (http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%.
A. Cardiovascular: Cerebellar infarction (grade 3 or 4) 1% 3 ; hemorrhage (grade 1 or 2) 2% 3 ; hypertension (grade 1 or 2) 14% to 37%, 3, 4 (grade 3 or 4) 1%. 3, 4 B. Hematologic: Anemia (grade 1 or 2) 40% to 50%, 3, 4 (grade 3 or 4) 7% 3, 4 ; febrile neutropenia (grade 3 or 4) 2% 3 ; leukopenia (grade 1 or 2) 37%, 3 (grade 3 or 4) 16% 3 ; lymphocytopenia (grade 1 or 2) 35%, 4 (grade 3 or 4) 23% 4 ; neutropenia (grade 1 or 2) 28% to 35%, 3, 4 (grade 3 or 4) 23% to 57% 3 ; thrombocytopenia (grade 1 or 2) 30% to 39%, 3, 4 (grade 3 or 4) 4% to 8%. 3, 4 C. Gastrointestinal: Epigastralgia (grade 1 or 2) 11% 3 ; nausea (grade 1 or 2) 27% 3 ; vomiting (grade 1 or 2) 15%, 3 (grade 3 or 4) 1%. 3 D. Hepatic: Increased aspartate aminotransferase/alanine aminotransferase (AST/ALT) (grade 1 or 2) 20% to 23%, 3, 4 (grade 3 or 4) 1% to 8%. 3, 4 E. Renal: Increased creatinine (grade 1 or 2) 5% 3 ; proteinuria (grade 1 or 2) 15% to 27%, 3, 4 (grade 3 or 4) 0%. 3, 4 F. Metabolic/endocrine: Hypokalemia (grade 1 or 2) 10%, 3 (grade 3 or 4) 4% 3 ; hyponatremia (grade 1 or 2) 4% to 12%, 3, 4 (grade 3 or 4) 7% to 23%. 3, 4 G. Infection: Infection with mild to moderate neutropenia (grade 1 or 2) 3%, 3 (grade 3 or 4) 15% 3 ; infection with moderate to severe neutropenia (grade 3 or 4) 6%. 3 H. Other: Fatigue (grade 1 or 2) 12% 3 ; tracheoesophageal fistula (grade 3 or 4) 1%. 3 b. Bilirubin >3 mg/dL-Do not give drug. 32 c. AST/ALT 60 units to 180 units-Give 50% dose 32 d. AST/ALT >180 units-Do not give drug 32 e. Bilirubin 1.5 mg/dL to 3 mg/dL and AST >3 times the upper limit of normal-Give 50% dose. 33 f. Bilirubin 1.5 mg/dL to 3 mg/dL and AST >180 units-Give 50% dose 34 3. Cisplatin: No information available 31
C. Myelosuppression
Grade 3 or 4 hematologic toxicity: Reduce etoposide and cisplatin dose to 60 mg/m 2 . 3
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